Cuorips
4894.TPharmaceutical
Financials · Consolidated
| Fiscal year ended | 2026-03 | 2025-03 | 2024-03 | 2023-03 |
|---|---|---|---|---|
| Revenue | ¥212m | ¥175m | ¥23m | — |
| Operating income | −¥1.1bn | −¥590m | −¥588m | — |
| Ordinary income | −¥1.0bn | −¥642m | −¥628m | — |
| Net income (owners) | −¥1.0bn | −¥644m | −¥632m | — |
| Total assets | ¥5.1bn | ¥5.7bn | ¥6.2bn | — |
| Net assets / equity | ¥4.8bn | ¥5.5bn | ¥6.0bn | ¥3.5bn |
| Operating cash flow | −¥1.1bn | −¥813m | −¥451m | — |
| EPS (basic) | ¥-124.54 | ¥-80.52 | ¥-85.86 | — |
From EDINET filings. Select any figure to open the report it came from. r = changed in a later filing (the report page shows the original). — = not reported in the filings structured so far.
Reports · 9
| Period | Form | Figures |
|---|---|---|
| 2025-04-01 → 2026-03-31 | Annual | 164 figures · EDINET |
| 2025-04-01 → 2025-09-30 | Half-year | 67 figures · EDINET |
| 2024-04-01 → 2025-03-31 | Annual | 154 figures · EDINET |
| 2024-04-01 → 2024-09-30 | Half-year | 43 figures · EDINET |
| 2023-04-01 → 2024-03-31 | Annual | 120 figures · EDINET |
| 2023-04-01 → 2023-12-31 | Quarterly Q3 | 19 figures · EDINET |
| 2023-04-01 → 2023-09-30 | Quarterly Q2 | 44 figures · EDINET |
| 2023-04-01 → 2023-06-30 | Quarterly Q1 | 29 figures · EDINET |
| 2022-04-01 → 2023-03-31 | Annual | 97 figures · EDINET |